<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 15 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 5 4 2 2 2 2 2 4;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:"Trebuchet MS";
panose-1:2 11 6 3 2 2 2 2 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
span.DefaultFontHxMailStyle
{mso-style-name:"Default Font HxMail Style";
font-family:"Arial",sans-serif;
color:windowtext;
font-weight:normal;
font-style:normal;
text-decoration:none none;}
span.org
{mso-style-name:org;}
span.locality
{mso-style-name:locality;}
span.region
{mso-style-name:region;}
span.postal-code
{mso-style-name:postal-code;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style></head><body lang=EN-CA link=blue vlink="#954F72" style='word-wrap:break-word'><div class=WordSection1><p class=MsoNormal><span class=DefaultFontHxMailStyle>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle>See below for a big bunch of articles wrt PCa.<o:p></o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle>Thx.<o:p></o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle>Glen<o:p></o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p><p class=MsoNormal>Sent from <a href="https://go.microsoft.com/fwlink/?LinkId=550986">Mail</a> for Windows</p><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p><div style='mso-element:para-border-div;border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal style='border:none;padding:0cm'><b>From</b></p></div><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:#FAFAFA;border-collapse:collapse'><tr><td width="100%" valign=top style='width:100.0%;padding:7.5pt 7.5pt 7.5pt 7.5pt'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;border-collapse:collapse'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td valign=top style='background:#FAFAFA;padding:6.75pt 0cm 6.75pt 0cm'></td></tr><tr><td valign=top style='background:white;padding:6.75pt 0cm 0cm 0cm;background:cover;-webkit-text-size-adjust:100%;background-size:cover;background-position-x:50%;background-position-y:50%' id=templateHeader><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 0cm 0cm 0cm;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;margin-left:-2.25pt;margin-right:-2.25pt;-webkit-text-size-adjust:100%'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm;max-width:100%;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%;word-break:break-word'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=d7a22b946e&e=d1cc1ed898"><strong><span style='font-size:18.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:red'>Sign up for Prostatepedia's Free Publications</span></strong></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table></td></tr><tr><td valign=top style='border:none;border-bottom:solid #EAEAEA 1.5pt;background:white;padding:0cm 0cm 6.75pt 0cm;background:cover;-webkit-text-size-adjust:100%;background-size:cover;background-position-x:50%;background-position-y:50%' id=templateBody><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><img border=0 width=564 height=162 style='width:5.875in;height:1.6875in' id="_x0000_i1031" src="https://mcusercontent.com/9154133f2e98aca1db87520cb/images/d701134e-9eff-4181-a839-0b935f4b3420.jpg"><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%;table-layout:fixed!important'><tr><td style='padding:13.5pt 13.5pt 13.5pt 13.5pt;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;border:none;min-width:100%;-webkit-text-size-adjust:100%'><tr><td style='border:none;border-top:solid #EAEAEA 4.5pt;padding:0cm 0cm 0cm 0cm;min-width:100%;-webkit-text-size-adjust:100%'></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=e665eff035&e=d1cc1ed898" title=""" "><span style='text-decoration:none'><img border=0 width=564 height=121 style='width:5.875in;height:1.2604in' id="_x0000_i1030" src="https://mcusercontent.com/9154133f2e98aca1db87520cb/images/c8663230-e624-1404-57ee-513a4edbaecc.png"></span></a><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%;table-layout:fixed!important'><tr><td style='padding:13.5pt 13.5pt 13.5pt 13.5pt;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;border:none;min-width:100%;-webkit-text-size-adjust:100%'><tr><td style='border:none;border-top:solid #EAEAEA 1.5pt;padding:0cm 0cm 0cm 0cm;min-width:100%;-webkit-text-size-adjust:100%'></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;margin-left:-2.25pt;margin-right:-2.25pt;-webkit-text-size-adjust:100%'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm;max-width:100%;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%;word-break:break-word'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt'><p class=MsoNormal style='line-height:150%'><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'>Curated by Merel Nissenberg, President, NASPCC<br><br>*NASPCC publishes both PROSTATEPEDIA Magazine and the weekly PROSTATEPEDIA DIGEST* </span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><strong><span style='font-size:24.0pt;line-height:150%;font-family:"Trebuchet MS",sans-serif;color:#202020'>New Links and Resources.</span></strong><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=5b2fac762a&e=d1cc1ed898"><span style='color:#007C89'>Prostatepedia's January/February Issue on Radiation Therapy</span></a></span><span lang=EN-US style='font-size:12.0pt;line-height:150%;color:#202020;mso-fareast-language:EN-US'> </span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'>AUA 2022: Stage Migration is Documented (Following USPSTF Screening Guidelines): <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=a509172919&e=d1cc1ed898"><span style='color:#007C89'> Prostate Cancer Grade Migration Documented </span></a><br> <br>AUA 2022: Better Survival of Metastatic Prostate Cancer Patients: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=0d4a7b058d&e=d1cc1ed898"><span style='color:#007C89'>Metastatic Prostate Cancer Survival Improved in Wake of Treatment Advances</span></a><br> <br>AUA 2022: Evaluation of ctDNA in Detecting Early Progression of Prostate Cancer on Immune Checkpoint Inhibitors: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=c9806e9e0b&e=d1cc1ed898"><span style='color:#007C89'>AUA 2022: Prospective Evaluation of ctDNA in Detecting Early Progression on Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Cancers </span></a><br> <br>Previous Prostate Surgery: Effect on mpMRI: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=525d3c9489&e=d1cc1ed898"><span style='color:#007C89'>Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series. </span></a><br> <br>AUA 2022: New AUA/ASTRO Guidelines for Localized Prostate Cancer: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=f4bec1d825&e=d1cc1ed898"><span style='color:#007C89'>New Guideline Gives Active Surveillance a Boost</span></a><br> <br>Mediterranean Style Diet and High-Intensity Interval Training for Men on ADT: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=8203b3979b&e=d1cc1ed898"><span style='color:#007C89'>Mediterranean Style Dietary Pattern with High Intensity Interval Training in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Pilot Randomised Control Trial.</span></a><br> <br>Oligometastatic Disease: Multimodality Treatment or ADT Alone: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=bc90d6f867&e=d1cc1ed898"><span style='color:#007C89'>Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone. </span></a><br> <br>Prostate Health Index (PHI) as a Reliable Biomarker: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=a60a327610&e=d1cc1ed898"><span style='color:#007C89'>Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis.</span></a><br> <br>ctDNA Correlates with PSA Kinetics in mCRPC in men treated with abiraterone or enzalutamide: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=a616264b9b&e=d1cc1ed898"><span style='color:#007C89'>Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. </span></a><br> <br>Prostate and Urine Microbiomes are linked to Human Prostate Cancer Risk Groups: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=09557839a8&e=d1cc1ed898"><span style='color:#007C89'>Prostate and Urine Microbiomes Are Linked to Human Prostate Cancer Risk Groups</span></a><br> <br>False-Negative MRI-Targeted Prostate Biopsies of Suspicious Pi-Rads 4 and 5 Lesions: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=27aa0e37b5&e=d1cc1ed898"><span style='color:#007C89'>Imaging and Patient-Related Factors Associated With False Negative MRI-Targeted Prostate Biopsies of Suspicious PI-RADS 4 and 5 Lesions</span></a><br> <br>Local Control After Image-Guided Radiotherapy of Oligometastatic Disease: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=8f6aa647f5&e=d1cc1ed898"><span style='color:#007C89'>Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). </span></a><br> <br>Metformin and Statins in Men with mCRPC: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=58f8b68c4b&e=d1cc1ed898"><span style='color:#007C89'>Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. </span></a><br> <br>New Artificial Intelligence-Based Tools in Prostate Cancer: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=2da612c7e6&e=d1cc1ed898"><span style='color:#007C89'>FDA OKs new AI-based breast, prostate cancer tools from RadNet</span></a><br> <br>AUA 2022: Artificial Intelligence PET Interpretation: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=e60874b926&e=d1cc1ed898"><span style='color:#007C89'>AUA 2022: Artificial Intelligence PET Interpretation vs Human Specialists: The LATAM Study </span></a><br> <br>AUA 2022: Harm-to-Benefit of Prostate Cancer Screening in Black Men for the last 3 Decades: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=b2427d6b1d&e=d1cc1ed898"><span style='color:#007C89'>AUA 2022: Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men </span></a><br> <br>AUA 2022: Niraparib plus Abiraterone and Prednisone for mCRPC in the QUEST Study: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=a74ef204e1&e=d1cc1ed898"><span style='color:#007C89'>AUA 2022: Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Results from the Phase 2 QUEST Study </span></a><br> <br>AUA 2022: Prevalence and Natural History of Non-Metastatic CRPC: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=91a681d3b3&e=d1cc1ed898"><span style='color:#007C89'>AUA 2022: Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis </span></a><br> <br>AUA 2022: Evaluation of Cardiovascular Risk for Men Starting ADT: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=b4c92210aa&e=d1cc1ed898"><span style='color:#007C89'>AUA 2022: Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis </span></a><br> <br>AUA 2022: Timing and Indications for Gallium-68 PSMA-PET/CT for Recurrence of Prostate Cancer After Radical Prostatectomy: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=5a231473cd&e=d1cc1ed898"><span style='color:#007C89'>AUA 2022: Optimizing Timing And Indications For 68Ga-PSMA PET/CT In Patients With Biochemical Recurrent Prostate Cancer After Radical Prostatectomy </span></a><br> <br>AUA 2022: Urinary Function After High Dose Intensity Modulated Radiation Therapy: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=20787f8f00&e=d1cc1ed898"><span style='color:#007C89'>AUA 2022: Urinary Function Following High Dose Intensity Modulated Radiotherapy for Clinically Localized Prostate Cancer</span></a><br> <br>AUA 2022: Comparison of Ability to Diagnose and Locate Prostate Cancer Between mpMRI and Pylarify: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=8d24c160c6&e=d1cc1ed898"><span style='color:#007C89'>AUA 2022: Update From the PEDAL Trial: A Prospective Single Arm Paired Comparison of Ability To Diagnose and Locate Prostate Cancer Between Multiparametric MRI and 18F-PSMA-PET/CT </span></a><br> <br>AUA 2022: Treatment Decision-Making Among Men with Localized Prostate Cancer: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=6e2622c21c&e=d1cc1ed898"><span style='color:#007C89'>AUA 2022: Preference Elicitation and Treatment Decision Making Among Men Diagnosed with Localized Prostate Cancer: Results from the Healium Trial </span></a><br> <br>AUA 2022: Active Surveillance for Localized Prostate Cancer: the AQUA Registry: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=13a1cb00cc&e=d1cc1ed898"><span style='color:#007C89'>AUA 2022: Active Surveillance for Low-Risk Prostate Cancer: Time Trends and Variation in the AUA Quality (AQUA) Registry </span></a><br> <br>New Randomized Trial in mCRPC – EVOLUTION (ANZUP 2001) - Ipilumimab plus Nivolumab and Lutetium – Enrolls its First Patient: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=0131fe999c&e=d1cc1ed898"><span style='color:#007C89'>First Patient Enrolled in New World-First Study into Prostate Cancer </span></a><br> <br>AUA 2022: AUA New Guidelines for Localized Prostate Cancer, Part II: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=2555b19edd&e=d1cc1ed898"><span style='color:#007C89'>Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery and Follow-up. </span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;margin-left:-2.25pt;margin-right:-2.25pt;-webkit-text-size-adjust:100%'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm;max-width:100%;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%;word-break:break-word'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt'><p class=MsoNormal style='line-height:150%'><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br></span><strong><span style='font-size:24.0pt;line-height:150%;font-family:"Trebuchet MS",sans-serif;color:#202020'>Reminders.</span></strong><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=eef7f392f7&e=d1cc1ed898"><span style='color:#007C89'>The 3RD Annual CPCC/UCSF Patient Conference On Prostate Cancer: “Using Current And Cutting-Edge Information To Help Make Informed Decisions” </span></a>October 15, 2022. </span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'>The 16<sup>th</sup> Annual Meeting of the National Alliance of State Prostate Cancer Coalitions (NASPCC) took place on January 28-30, 2022 in Washington, DC. A recording will be available soon.<br><br>The 17th Annual Meeting is being planned for October 7-9, 2022 in Washington DC.</span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'> <br>Please join NASPCC for a Webinar entitled “Prostate Cancer in Military Veterans” With Bruce Montgomery, MD, from The Seattle Cancer Care Alliance. Tuesday, June 14, 2022 due to schedule conflict. Register <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=94f7cbb21f&e=d1cc1ed898"><span style='color:#007C89'>here</span></a>.<br><br>NASPCC President, Merel Nissenberg, will be interviewing Basketball Great Grant Hill on May 31, 2022 about his pioneering work to increase the awareness of prostate cancer.<br><br>Special PSMA Presentation with Dr. Michael Hofman from Melbourne, Australia: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=f64a6c4622&e=d1cc1ed898"><span style='color:#007C89'>https://prosticpreceptorship2022.org/program/session8/</span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=c1a0db194a&e=d1cc1ed898"><span style='color:#007C89'>Merel Grey, president of NASPCC and Cal Ripken, Jr. Talk Prostate Cancer</span></a> <br><br><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=659b54b2f8&e=d1cc1ed898"><span style='color:#007C89'>Jessie Myers-Schecter talks about her father, Snuffy Myers, and what it was like to be the daughter of a prostate cancer patient. </span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=b31fb20edc&e=d1cc1ed898"><span style='color:#007C89'>NASPCC and CancerCare Online Prostate Cancer Patient Support Group</span></a><br><br><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=7700d302e8&e=d1cc1ed898"><span style='color:#007C89'>NASPCC Webinar Recordings Archive</span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'> *****Patients who have been treated with ADT and/or an anti-androgen for prostate cancer: we would like to interview you for the upcoming PROSTATEPEDIA Magazine!! Please contact <a href="mailto:mgrey@health.ucsd.edu"><span style='color:#007C89'>mgrey@health.ucsd.edu</span></a>*****</span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'> </span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><img border=0 width=564 height=436 style='width:5.875in;height:4.5416in' id="_x0000_i1029" src="https://mcusercontent.com/9154133f2e98aca1db87520cb/images/53731a5c-5b34-46de-a306-157337f67b36.jpg"><o:p></o:p></p></td></tr></table></td></tr></table></td></tr><tr><td valign=top style='background:#FAFAFA;padding:6.75pt 0cm 6.75pt 0cm;background:cover;-webkit-text-size-adjust:100%;background-size:cover;background-position-x:50%;background-position-y:50%' id=templateFooter><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td style='padding:0cm 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 7.5pt 6.75pt 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td style='padding:3.75pt 7.5pt 3.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=0 style='width:0cm;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td width=24 style='width:18.0pt;padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=c98f115a53&e=d1cc1ed898"><span style='text-decoration:none'><img border=0 width=24 height=24 style='width:.25in;height:.25in' id="_x0000_i1028" src="https://cdn-images.mailchimp.com/icons/social-block-v2/color-twitter-48.png" alt=Twitter></span></a><o:p></o:p></p></td></tr></table></td></tr></table></td></tr></table></td><td valign=top style='padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 7.5pt 6.75pt 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td style='padding:3.75pt 7.5pt 3.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=0 style='width:0cm;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td width=24 style='width:18.0pt;padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=a6cc9b80e1&e=d1cc1ed898"><span style='text-decoration:none'><img border=0 width=24 height=24 style='width:.25in;height:.25in' id="_x0000_i1027" src="https://cdn-images.mailchimp.com/icons/social-block-v2/color-facebook-48.png" alt=Facebook></span></a><o:p></o:p></p></td></tr></table></td></tr></table></td></tr></table></td><td valign=top style='padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 0cm 6.75pt 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td style='padding:3.75pt 7.5pt 3.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=0 style='width:0cm;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td width=24 style='width:18.0pt;padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=97e0861156&e=d1cc1ed898"><span style='text-decoration:none'><img border=0 width=24 height=24 style='width:.25in;height:.25in' id="_x0000_i1026" src="https://cdn-images.mailchimp.com/icons/social-block-v2/color-link-48.png" alt=Website></span></a><o:p></o:p></p></td></tr></table></td></tr></table></td></tr></table></td></tr></table></div></td></tr></table></div></td></tr></table></div></td></tr></table></div></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%;table-layout:fixed!important'><tr><td style='padding:7.5pt 13.5pt 18.75pt 13.5pt;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;border:none;min-width:100%;-webkit-text-size-adjust:100%'><tr><td style='border:none;border-top:solid #EEEEEE 1.5pt;padding:0cm 0cm 0cm 0cm;min-width:100%;-webkit-text-size-adjust:100%'></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;margin-left:-2.25pt;margin-right:-2.25pt;-webkit-text-size-adjust:100%'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm;max-width:100%;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%;word-break:break-word'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt'><p class=MsoNormal align=center style='text-align:center;line-height:150%'><em><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>Copyright © 2022 Prostatepedia NASPCC, All rights reserved.</span></em><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'> <br>You are receiving this email because you opted in via our website. <br><br><strong><span style='font-family:"Helvetica",sans-serif'>Our mailing address is:</span></strong> </span><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'><o:p></o:p></span></p><div><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span class=org><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>Prostatepedia NASPCC</span></span><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'><o:p></o:p></span></p><div><div><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>1999 Avenue of the Stars Ste 1100<o:p></o:p></span></p></div><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span class=locality><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>Los Angeles</span></span><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>, <span class=region>CA</span> <span class=postal-code>90067-4618</span><o:p></o:p></span></p></div><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'><br><a href="https://naspcc.us17.list-manage.com/vcard?u=9154133f2e98aca1db87520cb&id=c67ed256e6"><span style='color:#656565'>Add us to your address book</span></a><o:p></o:p></span></p></div><p class=MsoNormal align=center style='margin-bottom:12.0pt;text-align:center;line-height:150%'><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'><br><br>Want to change how you receive these emails?<br>You can <a href="https://naspcc.us17.list-manage.com/profile?u=9154133f2e98aca1db87520cb&id=c67ed256e6&e=d1cc1ed898&c=a8f768ecba"><span style='color:#656565'>update your preferences</span></a> <o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table></td></tr></table></div></td></tr></table></div></td></tr></table></div><p class=MsoNormal><img border=0 width=1 height=1 style='width:.0104in;height:.0104in' id="_x0000_i1025" src="https://naspcc.us17.list-manage.com/track/open.php?u=9154133f2e98aca1db87520cb&id=a8f768ecba&e=d1cc1ed898"><o:p></o:p></p><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p></div></body></html>